Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 10
Submit an article Journal homepage
264
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia

Huimin Jina Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Yu Zhua Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Ming Honga Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Yujie Wua Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Hairong Qiua Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Rong Wanga Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Hui Jina Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Qian Suna Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Jianxin Fua Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Jianyong Lia Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaView further author information
,
Sixuan Qiana Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaCorrespondence[email protected]
View further author information
&
Chun Qiaoa Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;b Key Laboratory of Hematology, Nanjing Medical University, Nanjing, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 2428-2437 | Received 15 Dec 2020, Accepted 03 Apr 2021, Published online: 24 May 2021

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (2)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.